UTv Videos

APPs can help in introducing genetic testing and in the interpretation of results, according to Kara Cossis, PA-C, MPH.

“And you look at most of the trials that were done in this space, about 2/3 of time, over 60% of time, management was changed based on a PET scan,” says Jason Hafron, MD.

"What we found is that it's very difficult to raise your review on these websites, but fairly easy to drop your review," says Jake Miller, MD.

“Put another way, with Apple Vision Pro, what we're hoping to do is have our residents be able to put on a headset and walk through a case before they actually walk into an operating room,” says Vikram M. Narayan, MD.

"I think what we definitively have is a device that's been around for over 50 years now that now we know significantly improves quality of life," says Andrew C. Peterson, MD, MPH.

Tim A. Richardson, MD, outlines the 2 key scenarios for utilizing genetic testing in clinical practice.

"It's often a balancing act of truly kind of pinning down people on what exactly they want to treat," says Landon Trost, MD.

“The 1 main assumption that we've been very wrong on although we've had the data for a long period of time, [is that] although we assume that the stone fragments are small enough to pass, oftentimes they don't,” says Thomas Mueller, MD.

"[Veterans] may be missing out on potentially life-saving treatments, and their family might also be missing out on some benefits as well," says Daniel Kwon, MD.

“Opportunity wise, I always say that if you don't perform the test, then you're limiting treatment options for your patients,” says Kara Cossis, PA-C, MPH.

“When a patient knows that there are so many tools that are there for people, it gives them hope. It gives their caregivers hope,” says Joy Maulik, CRNP.

"It's a little tedious to find these patients, but it's really critical. Otherwise, you're not going to get reimbursed for these therapies," says Jason Hafron, MD.

“We then talked a little bit about BCG unresponsive disease, which is a really hot topic,” says Gautam Jayram, MD.

“We're really excited as robotic surgeons, because this will be the first time in a couple decades that there'll be competition for robots, and that's only going to make things better,” says Ronney Abaza, MD, FACS.

“The guidelines have changed. They used to be called third-line therapies, and they're no longer quote "third-line" anymore, based on the new guidelines that have come out,” says Kari Bailey, MD.

“Part of the reason that we created this Working Group Session is to essentially highlight the role that APPs can play in building men's health practices,” says Andrew Y. Sun, MD.

“I would say, about 10 years ago, there was a real skepticism, a healthy skepticism, I would say, in the beginning. Now that has slowly changed into optimism,” says Arvin K. George, MD.

“I think that it is upon us as urologists to try to start to embrace this clinical accomplishment, and that being trying to make our patients as stone free as possible,” says Tom Mueller, MD.

"We only have so much time with our patients, but we want to show them that we support them," says Ava Saidian, MD.

"I cannot wait to see what the SMSNA is going to have in store next year," says Helen L. Bernie, DO, MPH.

“Certainly, I think when you have these inherent challenges or biases in the reimbursement aspects, it has to beg the question, does this or how will this impact the future of acquisition or passing down of these newer technologies?” says Kevin C. Zorn, MD, FRCSC, FACS.

"We found that almost half of them had suspicious findings as defined by the radiologist, but also that the positivity rate for PSAs below 0.5 were around 35%," says Eric Li, MD.

"I would basically look at these 3 things as the major things to be coming up," says Jitesh Dhingra, MD, FRCEM.

“On a lesion level, there were still more lesions detected with PSMA-PET, but not on a patient level,” says Jeremie Calais, MD, PhD.

"We were trying to understand how veterans were making decisions about germline testing for their prostate cancer," says Daniel Kwon, MD.

“I think this is the future, and if we don't go down that path and we don't explore, we're not going to make it better for us and for the patients,” says Geoffrey N. Sklar, MD, FACS.

"We were really surprised that we found that the anxiety components in the depression questions in those 3 questionnaires really improved drastically when we compared them to pretreatment vs post treatment," says Andrew C. Peterson, MD, MPH.

"For urologists that are interested in implementing Aquablation into their armamentarium, I am very envious, because anyone who is going to start doing Aquablation now is going to be using the HYDROS System," says Ravi Munver, MD.